Bio Buyout: MaxCyte Acquires SeQure

Cell-engineering company, MaxCyte, Inc., announced it will acquire SeQure Dx, which focuses on editing assessment services for cell and gene therapies, for $4.5 million. The all-cash deal includes additional consideration of up to $2.5 million if SeQure Dx meets predefined revenue thresholds, according to DealPulse’s M&A database, which...
spot_img

M&A

Analytics

Emerging Litigation Podcast

IP Protection, Secure Transactions, and Bored Apes: NFTs with Cameron Pick

NFTs – or non-fungible tokens – have taken the digital world by storm – or perhaps just a downloadable picture of a storm – promising to revolutionize not only the way we perceive, protect, purchase, and own digital assets,...

Around Law Street

spot_imgspot_imgspot_imgspot_img

Cryptocurrency

FOIA